Skip to main content
Neuro-Oncology logoLink to Neuro-Oncology
. 2018 Nov 5;20(Suppl 6):vi160. doi: 10.1093/neuonc/noy148.666

PATH-10. COPY NUMBER (CN)/SINGLE NUCLEOTIDE POLYMORPHISM (SNP) MICROARRAY ANALYSIS OF THE EGFR LOCUS IN GLIOSARCOMA

Lindsey Lowder 1, Ashley Woods 2, Stewart Neill 2, Jennifer Hauenstein 2, Saxe Debra 2, Brent Weinberg 2, Jeffrey Olson 3, Hui-Kuo Shu 4, Bree Eaton 5, Soma Sengupta 2
PMCID: PMC6216437

Abstract

Epidermal growth factor receptor (EGFR) is overexpressed or mutated in a variety of malignancies, most notably non-small cell lung cancer, colorectal cancer and glioblastoma (GBM). Glioblastoma is an aggressive primary brain tumor and 35–50% of glioblastomas show amplification of the EGFR locus (7p11.2). Interestingly, gliosarcoma, a histologic variant of GBM, has a lower frequency of EGFR alterations (4–8%). We characterized EGFR alterations in gliosarcoma using a DNA copy number/single nucleotide polymorphism cytogenomic microarray using formalin fixed paraffin embedded tissue. A retrospective search for “gliosarcoma” from our database yielded 19 cases on which microarray analysis was performed. Of these cases, 2 showed an amplification at the EGFR locus (13%), 5 cases showed a gain of the entire chromosome 7 (26.3%), 3 cases showed gains at loci other than EGFR (15.8%) and the remaining 9 cases were negative for chromosome 7 alterations (47.4%). Our preliminary data show that amplification of the EGFR locus are infrequent (13%) in gliosarcomas. These preliminary findings demonstrate antithetical results regarding EGFR amplifications in conventional glioblastoma compared to gliosarcoma and suggests there may be an alternate driver in gliosarcoma genesis.


Articles from Neuro-Oncology are provided here courtesy of Society for Neuro-Oncology and Oxford University Press

RESOURCES